Coeptis Therapeutics Holdings, Inc. (formerly Bull Horn Holdings Corp.) — Q3 2022 Form 10-Q
Issuer note: The filing identifies Coeptis Therapeutics Holdings, Inc. as the registrant; this differs from the “Z Squared Inc.” name in the request metadata. The financial statements cover the SPAC before its business combination, not the operating results of Coeptis Therapeutics, Inc.
Business context and reporting period
Unaudited results cover the three and nine months ended September 30, 2022. Before the combination, the company was a blank-check company and had not begun operating or generating revenue. It completed its business combination with Coeptis Therapeutics, Inc. on October 28, 2022, after quarter-end; that transaction is therefore a subsequent event, not part of the reported-period results.
Financial results and liquidity
- Revenue and margins: No operating revenue was generated. With no revenue, operating margin is not meaningful; operating costs were $543,663 for Q3 and $1,816,254 for the first nine months.
- Profit/loss: Q3 net loss was $305,107, versus net income of $4,176,909 in Q3 2021. Nine-month net income was $2,674,934, down from $16,446,001 in 2021. Earnings were significantly affected by non-cash changes in warrant fair value.
- Cash flow: Nine-month operating cash use was $564,335, compared with $322,550 in 2021. Investing activities provided $42,692,548, principally Trust Account withdrawals; financing activities used $42,518,728, principally share redemptions. Ending operating cash was $13,830.
- Assets and liquidity: At September 30, cash was $13,830, prepaid expenses were $17,137, and Trust Account marketable securities were $33,268,215. The company reported a working capital deficit of $1,863,212.
- Liabilities and debt: Total liabilities were $4,594,179, including $1,400,344 of accounts payable and accrued expenses, a $333,335 related-party advance, a $160,500 convertible promissory note, $450,000 of warrant liabilities, and a $2,250,000 deferred underwriting fee payable. The filing says the deferred fee was reduced to $500,000 for the Coeptis transaction; verify the amount ultimately payable at closing.
- Equity and redemptions: Shareholders’ deficit was $4,563,212. Following redemptions of 4,258,586 public shares for approximately $43.0 million, 3,241,414 public shares remained subject to possible redemption at quarter-end.
Material changes versus the prior comparable period
- Q3 shifted from net income to a net loss; operating costs increased from $100,017 to $543,663.
- Nine-month net income fell from $16.4 million to $2.7 million, largely reflecting a smaller warrant-liability fair-value gain: $4.3 million in 2022 versus $16.8 million in 2021. These gains are non-cash and should not be read as operating performance.
- Trust Account assets fell from $75.8 million at December 31, 2021 to $33.3 million at September 30, 2022, principally after shareholder redemptions. Operating cash fell from $404,345 to $13,830.
- Accounts payable and accrued expenses rose to $1.4 million from $139,927 at year-end 2021. The company also recorded related-party extension financing and a convertible note during 2022.
Outlook, risks, contingencies, and unusual items
- The company reported substantial doubt about its ability to continue as a going concern if it did not complete a business combination by the November 3, 2022 deadline. The combination with Coeptis closed on October 28, 2022, before that deadline.
- Management warned that the large redemptions left less cash for the transaction and could require additional financing, potentially on costly or dilutive terms. It also cited inflation, rising interest rates, COVID-19 effects, geopolitical uncertainty, and regulatory risks.
- The filing disclosed a material weakness in internal control over financial reporting, including accounting for complex financial instruments and redeemable shares, expense accruals, and liability classification. Disclosure controls were deemed ineffective. Management described remediation efforts but gave no assurance they would succeed.
- Warrant liabilities were measured at fair value, with changes recorded in earnings; some valuations relied on Level 3 inputs. The company also recorded a $58,100 nine-month fair-value loss on its related-party convertible note.
- There was no formal financial guidance. The filing reported no legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the registrant’s identity and the relationship, if any, to “Z Squared Inc.” in the request metadata.
- Review the October 28, 2022 transaction closing terms, financing and redemption outcomes, and the combined company’s capitalization and share dilution.
- Confirm the final deferred underwriting fee and repayment or settlement of related-party advances and the convertible note.
- Assess post-combination cash, liquidity needs, debt, operating results, and any going-concern disclosures in subsequent filings.
- Track remediation of the disclosed material weakness and whether subsequent reports identify additional control deficiencies.